S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:RETA

Reata Pharmaceuticals (RETA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$172.32
$172.46
50-Day Range
$168.70
$172.36
52-Week Range
$21.83
$172.46
Volume
1.99 million shs
Average Volume
1.09 million shs
Market Capitalization
$6.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$162.44

Reata Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
5.8% Downside
$162.44 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.02) to ($2.71) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.54 out of 5 stars

Medical Sector

880th out of 939 stocks

Pharmaceutical Preparations Industry

392nd out of 422 stocks

RETA stock logo

About Reata Pharmaceuticals Stock (NASDAQ:RETA)

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

RETA Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Top Growth Stocks for October 2023
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Biogen Completes Acquisition of Reata Pharmaceuticals
Reata Pharmaceuticals (RETA) Gets a Hold from Barclays
Biogen to Acquire Reata Pharmaceuticals
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?
Expert Ratings for Reata Pharmaceuticals
See More Headlines
Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RETA
Fax
N/A
Employees
321
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$162.44
High Stock Price Target
$173.00
Low Stock Price Target
$115.00
Potential Upside/Downside
-5.8%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
12 Analysts

Profitability

Net Income
$-311,900,000.00
Pretax Margin
-373.40%

Debt

Sales & Book Value

Annual Sales
$23.48 million
Book Value
($1.79) per share

Miscellaneous

Free Float
27,926,000
Market Cap
$6.58 billion
Optionable
Optionable
Beta
1.42

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

RETA Stock Analysis - Frequently Asked Questions

Should I buy or sell Reata Pharmaceuticals stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RETA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RETA, but not buy additional shares or sell existing shares.
View RETA analyst ratings
or view top-rated stocks.

What is Reata Pharmaceuticals' stock price target for 2024?

12 Wall Street research analysts have issued 1-year price targets for Reata Pharmaceuticals' stock. Their RETA share price targets range from $115.00 to $173.00. On average, they predict the company's share price to reach $162.44 in the next twelve months. This suggests that the stock has a possible downside of 5.8%.
View analysts price targets for RETA
or view top-rated stocks among Wall Street analysts.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) posted its earnings results on Monday, November, 8th. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.32) by $0.35. The company earned $7.40 million during the quarter, compared to analyst estimates of $2.07 million. The business's quarterly revenue was up 428.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.94) EPS.

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

Reata Pharmaceuticals (RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

This page (NASDAQ:RETA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners